Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Several other research firms have also commented on CTSO. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Thursday, April 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.12 on Friday. The company’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.01. The firm has a market capitalization of $70 million, a price-to-earnings ratio of -3.11 and a beta of 1.17. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. On average, equities research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in Cytosorbents during the 4th quarter valued at $30,000. Key Client Fiduciary Advisors LLC boosted its position in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after buying an additional 43,900 shares during the period. Renaissance Technologies LLC boosted its position in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp lifted its position in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Cytosorbents during the 4th quarter valued at about $99,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.